Key Points
- Insider sale: EVP Alicia Olivo sold 20,916 shares on Nov. 25 at an average price of $12.00 for about $250,992, cutting her stake by 40.22% to 31,083 shares; the transaction was disclosed in an SEC Form 4 filing.
- Mixed financials: NeoGenomics beat quarterly EPS and revenue estimates ($0.03 vs $0.02; $187.8M vs $183.85M) with revenue up 12% year-over-year, but the company still posts a negative net margin (-16%) and guided FY2025 EPS to $0.080–0.120 while analysts expect roughly -0.2 EPS.
- Market and analyst view: Shares trade near $12.10 (50/200-day MAs $9.89/$8.08) with a $1.57B market cap, and Wall Street’s consensus is a "Hold" rating with an average price target of $13.11.
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) EVP Alicia Olivo sold 20,916 shares of NeoGenomics stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total transaction of $250,992.00. Following the sale, the executive vice president owned 31,083 shares of the company's stock, valued at $372,996. The trade was a 40.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
NeoGenomics Price Performance
Shares of NEO opened at $12.10 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.91 and a quick ratio of 3.58. The company's fifty day moving average price is $9.89 and its 200-day moving average price is $8.08. NeoGenomics, Inc. has a 1-year low of $4.72 and a 1-year high of $19.11. The firm has a market capitalization of $1.57 billion, a PE ratio of -13.75 and a beta of 1.67.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.01. The company had revenue of $187.80 million during the quarter, compared to analyst estimates of $183.85 million. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.The firm's quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the business posted $0.05 EPS. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. On average, equities research analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current year.
Institutional Investors Weigh In On NeoGenomics
Hedge funds have recently bought and sold shares of the stock. Aster Capital Management DIFC Ltd grew its stake in shares of NeoGenomics by 42.5% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company's stock worth $26,000 after purchasing an additional 997 shares during the period. Headlands Technologies LLC purchased a new stake in NeoGenomics during the second quarter worth $32,000. Brooklyn Investment Group purchased a new stake in NeoGenomics during the first quarter worth $35,000. CWM LLC grew its position in NeoGenomics by 42.6% during the first quarter. CWM LLC now owns 6,299 shares of the medical research company's stock valued at $60,000 after buying an additional 1,883 shares during the period. Finally, AlphaQuest LLC purchased a new position in NeoGenomics in the first quarter valued at $60,000. Hedge funds and other institutional investors own 98.50% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on NEO shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NeoGenomics in a report on Monday. TD Cowen raised their price target on shares of NeoGenomics from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Friday, September 12th. Leerink Partners set a $14.00 price objective on shares of NeoGenomics in a research note on Tuesday, October 28th. Cowen reiterated a "buy" rating on shares of NeoGenomics in a research note on Friday, September 12th. Finally, Piper Sandler set a $11.00 target price on shares of NeoGenomics and gave the stock an "overweight" rating in a report on Monday, August 4th. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $13.11.
Get Our Latest Analysis on NeoGenomics
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
